文献速递乳腺US乳腺X线

筛查性数字乳腺断层摄影召回的未钙化病灶:单用超声与超声联合额外乳腺X线摄影视图的前瞻性诊断评估

Diagnostic Evaluation of Recalled Noncalcified Lesions Using Ultrasound Alone Versus Ultrasound Plus Additional Mammographic Views: A Prospective Study.
PubMed 文献 · AJR Am J Roentgenol · 2021-12-15

前瞻性单臂研究纳入399例女性430个筛查DBT召回的未钙化病灶,71.2%病灶仅用诊断性超声评估,28.8%联合诊断性乳腺X线摄影。93个活检病灶中38个为癌(均为浸润性),其中92.1%仅用超声评估;中位随访25个月,初始良性评估者中检出6个癌。作者认为单用超声对召回的非钙化肿块有效,不对称病灶可能以诊断性乳腺X线摄影为佳而无需额外超声,结构扭曲仍需诊断性乳腺X线摄影和超声。

要点

  • 筛查DBT召回的非钙化肿块可考虑优先行超声评估(作者建议)。
  • 不对称病灶可能以诊断性乳腺X线摄影为佳,无需额外超声(作者结论)。
  • 结构扭曲仍需要诊断性乳腺X线摄影和超声评估(作者结论)。

核心结论

  • 单用超声对筛查断层摄影召回的非钙化肿块诊断评估有效;不对称病灶可能以诊断性乳腺X线摄影为佳而无需额外超声,结构扭曲仍需诊断性乳腺X线摄影和超声。

研究设计与样本

  • 前瞻性单臂管理策略研究,2017年7月10日至2019年6月6日纳入399例女性430个筛查DBT召回的未钙化病灶(平均年龄60±12岁),初始诊断性超声按研究方案进行,额外诊断性乳腺X线摄影由放射科医生酌情决定。

关键影像表现/征象

  • 93个病灶行穿刺活检,其中38个(40.9%)为癌,均为浸润性癌。
  • 38个癌中35个(92.1%)仅用超声评估,3个(7.9%)用超声联合诊断性乳腺X线摄影评估。
  • 中位随访25个月,初始良性评估者中检出6个癌(3个仅用超声,3个用超声联合诊断性乳腺X线摄影)。
  • 单用超声有2个假阴性癌(1个结构扭曲在随访时发现,1个肿块在初始发现时经立体定向活检)。

诊断标准与关键数值

  • 召回病灶中仅用超声评估的比例:肿块93.7%(178/190)、局灶性不对称60.0%(51/85)、不对称46.1%(53/115)、进展性不对称69.2%(9/13)、结构扭曲55.6%(15/27)。
  • 全部430个病灶中71.2%(306/430)仅用超声,28.8%(124/430)用超声联合诊断性乳腺X线摄影。

临床应用与阅片要点

  • 放射科医生应考虑对DBT召回的非钙化肿块首先行超声检查(作者建议)。
  • 超声阴性时省略诊断性乳腺X线摄影的假阴性率低(作者结论)。

局限性

  • 额外诊断性乳腺X线摄影由放射科医生酌情决定,非随机分配。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND. The diagnostic performance of digital breast tomosynthesis (DBT) has been shown to be equal to that of diagnostic mammography. However, the value of additional mammographic views in diagnostic evaluations remains unclear. OBJECTIVE. The purpose of this study was to compare the performance of diagnostic breast ultrasound (US) alone with that of combined US and diagnostic mammography for specific noncalcified recalled abnormalities detected on screening DBT. METHODS. This was a prospective study with a single-arm management strategy. Women recalled for noncalcified lesions on screening DBT underwent initial diagnostic US as part of the study protocol. Additional diagnostic mammography was performed at the discretion of the radiologist. Imaging assessment decisions determined by BI-RADS assessments and management recommendations, biopsy outcomes, and follow-up were recorded using case report forms completed on the day of the diagnostic evaluation and stored in the electronic medical record. RESULTS. From July 10, 2017, to June 6, 2019, a total of 430 recalled noncalcified lesions in 399 women (mean age, 60 ± 12 [SD] years) were included. US alone was performed for 71.2% (306/430) of lesions, whereas US with diagnostic mammography was performed for 28.8% (124/430). Of the recalled lesions, 93.7% (178/190) of masses, 60.0% (51/85) of focal asymmetries, 46.1% (53/115) of asymmetries, 69.2% (9/13) of developing asymmetries, and 55.6% (15/27) of architectural distortions were evaluated with US alone. Of 93 lesions that underwent needle biopsy, 40.9% (38/93) were cancers, all of which were invasive. Thirty-five of 38 (92.1%) cancers were evaluated by US alone, whereas three (7.9%) were evaluated with US and diagnostic mammography. At a median follow-up of 25 months, six cancers were identified (three with US alone and three with US plus diagnostic mammography) in patients with initially benign workup. US alone had two false-negative cancers (one architectural distortion identified at follow-up and one mass biopsied stereotactically at initial detection). CONCLUSION. US alone is effective in the diagnostic evaluation of noncalcified masses recalled on screening tomosynthesis. For asymmetries, diagnostic mammography may be best without the need for additional US, whereas architectural distortions still warrant diagnostic mammography and US. CLINICAL IMPACT. Radiologists should consider performing US first for DBT-recalled noncalcified masses. Omitting diagnostic mammography when US is negative has a low false-negative rate.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Porembka, Seiler, Sharifi, et al. Diagnostic Evaluation of Recalled Noncalcified Lesions Using Ultrasound Alone Versus Ultrasound Plus Additional Mammographic Views: A Prospective Study. AJR Am J Roentgenol. 2021. PMID: 34910533. doi:10.2214/AJR.21.26700

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。